VEGF Receptor 2 protein (Fc Chimera) (ab54259)
Constituents: PBS, pH 7.4
Our Abpromise guarantee covers the use of ab54259 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Biological Activity: The activity of sVEGFR2/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- CD309CD309 antigenFetal liver kinase 1
- FLK-1FLK1KDRKinase insert domain receptorKinase insert domain receptor (a type III receptor tyrosine kinase)KRD1Ly73Protein tyrosine kinase receptor FLK1Protein-tyrosine kinase receptor flk-1Tyrosine kinase growth factor receptorVascular endothelial growth factor receptor 2VEGFRVEGFR 2VEGFR-2VEGFR2VGFR2_HUMAN
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
References for VEGF Receptor 2 protein (Fc Chimera) (ab54259)
This product has been referenced in:
- Kaczmarek MM et al. Assessment of VEGF-receptor system expression in the porcine endometrial stromal cells in response to insulin-like growth factor-I, relaxin, oxytocin and prostaglandin E2. Mol Cell Endocrinol 291:33-41 (2008). Read more (PubMed: 18562087) »